Hypervision Surgical raised £17 million (about $23 million) in a Series A financing to scale its hyperspectral imaging platform for surgical use. The system combines spectral sensing with cloud-enabled AI analytics to provide surgeons real-time tissue physiology insights that are not otherwise visible. The funding is positioned to advance product development and deployment, aiming to reduce uncertainty during procedures by improving intraoperative visualization and differentiation of tissue states. For med-tech and translational biotech stakeholders, the round highlights continued investment in AI-enabled imaging as a clinical decision-support layer across surgical oncology and precision procedures.